Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

United Kingdom national guideline on the management of molluscum contagiosum.

BIBLIOGRAPHIC SOURCE(S)

  • Clinical Effectiveness Group, British Association for Sexual Health and HIV (BASHH). United Kingdom national guideline on the management of molluscum contagiosum. London (UK): British Association for Sexual Health and HIV (BASHH); 2008 Feb 15. 5 p. [11 references]

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD). 2002 national guideline on the management of molluscum contagiosum. London: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD); 2002. Various p.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Definitions of the levels of evidence (I-IV) and grades of recommendation (A-C) are defined at the end of the "Major Recommendations" field.

Diagnosis

  • This is usually based on characteristic clinical appearance.
  • The main differential diagnosis is with genital warts, which are neither smooth nor umbilicated.
  • The core of lesions can be examined by electron microscopy, under which typical poxvirus-like particles will be seen.

Management

General Advice

As the natural history is of spontaneous regression of lesions, treatment is offered for cosmetic reasons only.

Further Investigation

  • As other sexually transmitted infections (STIs) may co-exist; a full screen for these should be undertaken (Level of evidence III, Grade of recommendation B).
  • Human immunodeficiency virus (HIV) testing is recommended in patients presenting with facial lesions (Level of evidence III, Grade of recommendation B).

Treatment

The aim is tissue destruction, with viral demise accompanying this. There are no medicines licensed for the treatment of molluscum contagiosum (MC) in the United Kingdom (UK).

Recommended Regimens

  • Cryotherapy – apply liquid nitrogen until a halo of ice surrounds the lesion. Repeat applications may be necessary (Level of evidence IV, Grade of recommendation C).
  • Expression of the pearly core, either manually or using forceps (Level of evidence IV, Grade of recommendation C).
  • Piercing with an orange stick, with or without the application of tincture of iodine or phenol (Level of evidence IV, Grade of recommendation C).
  • Curettage or diathermy may be carried out under local anaesthesia (Level of evidence IV, Grade of recommendation C).
  • Podophyllotoxin cream (0.5%) can be self-applied in men (Level of evidence Ib, Grade of recommendation A).
  • Imiquimod 5% cream can be self-applied in men (Level of evidence Ib, Grade of recommendation A).
  • In patients with HIV infection, the introduction of highly active antiretroviral therapy may lead to the resolution of lesions (Level of evidence III, Grade of recommendation B).

Allergy

  • Treatments to which there is known hypersensitivity should be avoided

Pregnancy and Breastfeeding

  • Cryotherapy and other, purely destructive methods are safe.
  • Podophyllotoxin is contraindicated. The British National Formulary advises that Imiquimod should be used with caution.

Sexual Partners

  • Contact tracing of partners is unnecessary

Definitions:

Levels of Evidence

Ia: Evidence obtained from meta-analysis of randomised controlled trials

Ib: Evidence obtained from at least one randomised controlled trial

IIa: Evidence obtained from at least one well designed controlled study without randomisation

IIb: Evidence obtained from at least one other type of well designed quasi-experimental study

III: Evidence obtained from well designed non-experimental descriptive studies such as comparative studies, correlation studies, and case control studies

IV: Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities

Grading of Recommendations

A (Evidence levels Ia, Ib)

  • Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.

B (Evidence levels IIa, IIb, III)

  • Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of recommendation.

C (Evidence level IV)

  • Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities. Indicates absence of directly applicable studies of good quality.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for selected recommendations (see "Major Recommendations").

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Clinical Effectiveness Group, British Association for Sexual Health and HIV (BASHH). United Kingdom national guideline on the management of molluscum contagiosum. London (UK): British Association for Sexual Health and HIV (BASHH); 2008 Feb 15. 5 p. [11 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

1999 Aug (revised 2008 Feb 15)

GUIDELINE DEVELOPER(S)

British Association for Sexual Health and HIV - Medical Specialty Society

SOURCE(S) OF FUNDING

Not stated

GUIDELINE COMMITTEE

Clinical Effectiveness Group (CEG)

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Author: Gordon Scott, Lauriston Building, Edinburgh

Clinical Effectiveness Group (CEG) Members: Dr Keith Radcliffe, Whittal Street Clinic, Birmingham (BASHH); Dr Imtyaz Ahmed-Jusuf, Nottingham City Hospital (BASHH); Dr David Daniels, West Middlesex Hospital (Chair NAG); Dr Mark FitzGerald, Taunton and Somerset (BASHH); Dr Neil Lazaro (RCGP); Dr Guy Rooney, Swindon and Oxford (RCP); Dr Gill McCarthy, Kingston Hospital (BASHH)

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Conflict of Interest: None

This guideline was commissioned and edited by the Clinical Effectiveness Group (CEG) of the British Association for Sexual Health and HIV (BASHH), without external funding being sought or obtained.

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD). 2002 national guideline on the management of molluscum contagiosum. London: Association for Genitourinary Medicine (AGUM), Medical Society for the Study of Venereal Disease (MSSVD); 2002. Various p.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on December 8, 2000. The information was verified by the guideline developer on January 12, 2001. This summary was updated on August 5, 2002. This summary was updated by ECRI Institute on June 24, 2008. The updated information was verified by the guideline developer on June 30, 2008.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developers and/or BMJ Publishing Group's copyright restrictions. Reproduction and use of this guideline is permitted provided that (a) the original content is not changed or edited; and, (b) any content derived from the original guideline is acknowledged as that of the author(s) and responsible organizations.

Readers wishing to download and reproduce material for purposes other than personal study or education should contact BMJPG to seek permission first. Contact: BMJ Publishing Group, BMA House, Tavistock Square, WC1H 9JR, UK.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo